Immunotherapy

Do you have a BMI threshold where you would convert to weight-based dosing over flat dosing? Are certain agents of more or less concern - PD-1, PD-L1,...

3 Answers available

How do you prescribe a steroid taper for radiation and checkpoint inhibitor related pneumonitis?

I've seen a handful of fatal radiation pneumonitis associated with rapid steroid tapers by the non-treating physicians. How do you recommend prescribi...

1 Answer available

Would you ever consider definitive thoracic RT with concurrent immunotherapy in Stage III NSCLC?

I recently saw a patient who had been treated with concurrent pembrolizumab-RT elsewhere. Is this an acceptable practice outside the setting of a clin...

2 Answers available

Do you stop PPI when starting patients on immunotherapy?

1 Answer available

Do you routinely obtain CPS assay to assess candidacy for chemoimmunotherapy in newly diagnosed metastatic esophageal/GEJ/gastric adenocarcinoma?

Is it necessary to test CPS given the FDA approvals are not contingent on CPS %? If you do test, do you check 28-8 (nivolumab), 22C3 (pembroliz...

2 Answers available

What initial systemic approach will you recommend for metastatic pMMR HER2- esophageal/GEJ/gastric adenocarcinoma with CPS of 0-4?

Do you view CPS < 1% or 1-4% separately? Do you view the incremental benefit of adding immunotherapy still advantageous given relatively poor outco...

3 Answers available

What impacts your decisions regarding the use of immunotherapy in metastatic G/E/GEJ cancers overall in light of variations in FDA approval, guidelines, and trial data?

Do you go by FDA approval alone, or incorporate other data into your treatment decisions? How do you view updated recent presentation of CM-649 ...

3 Answers available

What are your considerations for choice of immunotherapy agent with patients with metastatic pMMR HER2- esophageal/GEJ/gastric adenocarcinoma with CPS >=10?

Are there meaningful differences in the CHECKMATE 649 and KEYNOTE 590 studies to guide this decision?

2 Answers available

In patients who receive neoadjuvant pembrolizumab and chemotherapy for TNBC, how will you manage adjuvant treatment if they have a germline BRCA mutation?

Would you continue pembrolizumab? Would you introduce olaparib? If using both, how would you sequence?

5 Answers available

What is your preferred first line treatment approach for a patient with PDL-1 high (>50%) NSCLC presenting with CNS mets?

If a patient is asymptomatic at presentation, how do you incorporate local treatment options (RT/surgery) and when?

2 Answers available

What are your recommendations for a patient with metastatic non-mutated lung adenocarcinoma who previously had headaches responsive to prednisone but with negative temporal artery biopsy for GCA?

For medical oncologists, would you offer a PD-1/L1 inhibitor? For other subspecialties, how would you counsel the oncologist regarding the risk of usi...

1 Answer available

Would you hold off on whole brain radiotherapy for a patient with metastatic NSCLC and multiple asymptomatic brain metastases and will be starting immunotherapy?

5 Answers available

What data do you view as most impactful to treatment decisions in 1L metastatic ccRCC?

How do you weigh the various efficacy endpoints in the trials of novel combinations in ccRCC? Are there specific clinical populations that you ...

3 Answers available

For patients with metastatic triple negative breast cancer on nab-paclitaxel + atezolizumab who have an ongoing response, are you continuing immunotherapy after the FDA withdrawal of atezolizumab?

1 Answer available

In a patient with metastatic TNBC on chemoimmunotherapy for several years and a near complete response, would you consider an immunotherapy holiday?

The patient was started on chemoimmunotherapy 3 years ago. Recent scans show small treated brain metastases (s/p RT several years ago) and no disease ...

2 Answers available

Do you hold immunotherapy when administering lung SBRT?

One example of this scenario would be a patient receiving consolidative durvalumab after chemoRT for stage III NSCLC who develops a new peripheral lun...

3 Answers available

Is it safe to deliver SBRT with concurrent immunotherapy to head and neck sites of progressive metastatic disease?

What doses and constraints do you use?

1 Answer available

What is your approach to immunotherapy-related pancreatitis?

How do you manage the initial event, including length of steroid taper and the role of pancreatic enzyme monitoring? What is your experience of subse...

1 Answer available

How do you approach the management of SSc-ILD in a patient on immune checkpoint therapy?

1 Answer available

Are there circumstances where you would recommend every 6 week dosing schedule for pembrolizumab monotherapy?

I am considering every 6 week pembrolizumab dosing in patients >70 years old in whom I want to reduce clinic visits for, especially in the context ...

3 Answers available

How would you approach a BRAF negative metastatic melanoma patient on immune checkpoint inhibitor therapy with enlarging, symptomatic brain lesions that had previously been treated with SRS?

If on pembrolizumab or nivolumab, when would you escalate to ipilimumab/nivolumab?

1 Answer available

Would you hold rituximab for newly diagnosed B-cell lymphoma if the patient is COVID-19 positive?

What if the patient has a history of confirmed COVID-19 but has since recovered?

1 Answer available

How do you manage pneumonitis in patients with Stage III NSCLC receiving durvalumab?

How do you prescribe a steroid taper? If it is grade 2, would you keep them on low dose prednisone while continuing? When do you feel comfortable re-c...

2 Answers available

Are you altering your use of immune checkpoint inhibitors given the risk of immune-related pneumonitis and the COVID-19 outbreak?

2 Answers available

Is your approach to managing immune related adverse events altered at all in light of COVID-19?

2 Answers available

Do you offer consolidative thoracic radiation for oligometastatic NSCLC following upfront immunotherapy?

In patients who have a mixed response or progression and are poor candidates for other systemic agents, would you consider consolidating the chest? Wo...

2 Answers available

How do you approach further treatment of patients who develop grade 2-3 immune colitis from nivolumab/ipilimumab prior to completion of the 4 ipilimumab doses?

Do you re-challenge with nivolumab alone, change from nivo 1/ipi 3 to nivo 3/ipi 1 upon re-challenge, or stop immunotherapy altogether if grade 3?&nbs...

1 Answer available

Before re-challenging a patient with ICI after grade 1-2 pneumonitis, do you re-image to confirm resolution of pneumonitis?

1 Answer available

Is there a period of time after which you would not resume ICI after a patient has had an irAE and required a prolonged steroid taper?

1 Answer available

Would the need for infliximab/MTX/nonsteroidals to control initial irAE affect your decision to rechallenge these patients with ICI?

1 Answer available

How do you decide whether or not to give immunotherapy in patients with a history of an isolated, severe autoimmune event?

For instance, not chronic autoimmune diseases (eg RA, IBD) that may relapse/remit but events like Guillan Barre syndrome that is not likely to recur b...

1 Answer available

At what doses of steroids would you feel it's acceptable to either initiate or resume checkpoint inhibitors?

Particularly if steroids are used for non-immunotherapy toxicities (COPD exacerbation, brain edema, autoimmune diseases to name a few) -- when do you ...

1 Answer available

How do you choose 1st line therapy for recurrent cervical cancer?

Would you be more or less likely to use a cisplatin-containing regimen if a patient had previously responded to chemoradiation with concurrent cisplat...

1 Answer available

How do you determine which systemic therapy to recommend in the 2nd line setting for metastatic, PD-L1 NEGATIVE cervical cancer?

1 Answer available

How do you monitor response for stage III NSCLC patients receiving consolidation immunotherapy?

CT or PET? If so, how often?

3 Answers available

Does consolidation durvalumab increase the risk of pneumonitis in Stage III NSCLC?

Rate of pneumonitis was low in the PACIFIC trial but does it mirror the real world setting? We are seeing increased pneumonitis in our practice.

2 Answers available

Is pembrolizumab considered standard of care in the 2nd line treatment of recurrent cervical cancer?

Does the phase II KN-158 provide sufficient evidence to change management?

1 Answer available

Would you recommend 1st line pembrolizumab for PD-L1 positive recurrent/metastatic cervical cancer patient who is not a candidate for or refuses chemotherapy?

1 Answer available

When do you recommend PD-L1 testing for patients with recurrent cervical cancer?

Should this be done at the time of recurrence or after failure of 1st line therapy for recurrence?

1 Answer available

Can you use immunotherapy in patients with liver transplants?

With increasing utility of immunotherapy across cancer types, patients with history of solid organ transplants may face need for cancer IO. How do you...

1 Answer available

Do you stop consolidative durvalumab after one year as per the PACIFIC trial or continue if the patient is otherwise tolerating well?

1 Answer available

How early have you been able to detect a response with CAR-T in patients with relapsed DLBCL?

3 Answers available

When do you consider employing the 4-week dosing schedule for nivolumab?

The FDA has approved the new dosing schedule of Nivolumab 480 mg every 4 weeks for multiple disease sites (melanoma, RCC, urothelial carcinoma, SCC of...

5 Answers available

What is the role of upfront pembrolizumab in metastatic PD-L1 positive NSCLC presenting with SVC syndrome?

Would starting with chemotherapy be preferred in this situation and consider concurrent radiation, then switch over to Pembrolizumab once some control...

1 Answer available

Is there a role for DDR gene mutation or tumor mutation burden/load in predicting response to immunotherapy in urothelial cancer?

1 Answer available

How do you choose among the available PD-1/PDL-1 inhibitors approved for metastatic bladder cancer?

There are now five PD-1/PDL-1 inhibitors approved for metastatic bladder CA, one (Atezolizumab) as first-line therapy in cisplatin-ineligible patients...

2 Answers available

What is the your choice of treatment after progression or AE following pembrolizumab in metastatic melanoma?

Patient does not have BRAF mutation.

1 Answer available

Do you routinely hold immunotherapy during whole brain radiation?

2 Answers available

Would you treat a patient with HIV or hepatitis C with an anti-PD-1 agent?

These patients have been largely excluded from these trials. What if the infection is well controlled?

3 Answers available

Is it necessary to hold immunotherapy during a 4-6wk steroid taper after resolution of immunotherapy related toxicity?

Would you ever considering re-starting immunotherapy before completing the taper? According to the new guildelines on managing immunotherapy related ...

1 Answer available

When discussing immunotherapy with patients, how do you frame the conversation in a way that acknowledges the fact that many patients do not respond but allows for hope for a durable response?

1 Answer available

Can ctDNA be used to evaluate response to checkpoint inhibitors in NSCLC when pseudoprogression is suspected on CT imaging?

1 Answer available

How do you choose between single agent versus combination checkpoint inhibitors for BRAF Wildtype metastatic melanoma?

1 Answer available

Are certain PD-L1 assays considered more accurate or reliable than others for NSCLC?

How do the different assays compare when choosing a specific immunotherapy, and does this change for first vs second (or beyond) line of therapy?

1 Answer available

How do you manage immune-related toxicity from checkpoint inhibitors that is refractory to initial steroid therapy?

What immunosuppressive agents are used and in what order? Does your approach differ depending on the organ involved, e.g. colitis vs. pneumoniti...

1 Answer available

Would you continue immune checkpoint inhibitor therapy in a metastatic NSCLC patient with CNS failure if the systemic disease is otherwise controlled?

Does the extent/duration of systemic disease control (complete response vs. stable disease, for example) influence your decision? What about whe...

1 Answer available

For newly diagnosed BRAF mutated melanoma with brain metastases, do you prefer to start with targeted therapy or with immunotherapy?

1 Answer available

Would you use immune checkpoint inhibitors in patients with well-compensated liver cirrhosis?

Does the risk of severe inflammation of the liver lead you to choose other therapies in in this population? What about in patients with mild liv...

1 Answer available

For lung cancer patients who experience grade 3/4 toxicity from a PD-1 inhibitor necessitating cessation of therapy, but whose tumor has responded to the treatment, do you consider restarting PD-1 inhibitor therapy at the time when they progress again?

Would you consider giving the therapy with concominant steroids, or with a dose reduction?

1 Answer available

Are there any subgroups of patients with advanced/metastatic NSCLC for whom you are using PD-1 inhibitors in the first-line setting, either alone or in combination with platinum-based chemotherapy?

Also, are you testing for PD-L1 routinely prior to initiation of first-line systemic therapy?

1 Answer available

When giving palliative lung radiation to a patient on immune checkpoint blockade for NSCLC, do you hold immunotherapy?

If not what radiation fractionation regimen is preferred for otherwise good KPS patient?

1 Answer available

What is your preferred third-line treatment for a patient with metastatic renal cell carcinoma who has had progression of disease on both initial VEGFR-TKI therapy and second-line nivolumab?

For patients who remain fit and interested in treatment, but for whom a clinical trial is not an option, what systemic therapy do you reach for in thi...

3 Answers available

How do you sequence systemic therapies for recurrent/metastatic head/neck cancer following the recent approval of pembrolizumab?

Do HPV and/or PD-L1 status influence your decision making?

1 Answer available

Are you routinely offering nivolumab for second-line treatment of small cell lung cancer?

Based on recently published data from CheckMate 032, do you now offer nivolumab to small cell patients who have progressed after first-line chemothera...

0 Answers available

Do you routinely include sipuleucel-T as one of your lines of systemic therapy for metastatic castration resistant prostate cancer?

If so, how do you sequence this with other therapies? In addition, in the absence of an effect on radiographic PFS or serum PSA, how do you asse...

1 Answer available

For a patient with metastatic urothelial cancer who has progressed on platinum-based chemotherapy, do you test for tumor PD-L1 expression prior to choosing atezolizumab as second-line treatment?

In the IMvigor 210 trial, increased PD-L1 expression in patients’ tumors was associated with response to atezolizumab, but some patients whose t...

1 Answer available

How should RT be combined with immunotherapy to generate an abscopal response?

Is there any consensus regarding the optimal RT dose, fractionation, and timing to the best abscopal response? What is the optimal metastatic site to ...

1 Answer available

Other than part of a clinical trial or for its FDA-approved indication (second-line therapy for metastatic squamous-cell NSCLC), when do you offer nivolumab to your patients with NSCLC?

For example, should nivolumab be considered standard second-line therapy for adenocarcinoma patients? Can it be considered for first-line thera...

0 Answers available

Is there a role for anti PD-1/checkpoint inhibitors or other immunotherapies with radiation?

Are there any open clinical trials testing this?

1 Answer available

Papers discussed in this category

The New England journal of medicine, 2015-10-22

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Nature reviews. Rheumatology, 2022 Oct 05

Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases.

Oncoimmunology, 2023 Oct 30

Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseases.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-11-01

Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.

The Lancet. Oncology, 2016-07

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.

Cancer Treat. Rev., 2016-04-01

Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy.

Immunotherapy, 2016-10

Autoimmune meningoencephalitis in a melanoma patient treated with ipilimumab.

J Thorac Oncol, 2017-02-01

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.

JAMA oncology, 2017-08-01

A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer.

N Engl J Med, 2015 May 31

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

Lancet (London, England), 2017-01-07

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

The New England journal of medicine, 2017-03-16

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.

J. Clin. Oncol., 2018-06-10

Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers.

JCO Precision Oncology, 2017 Sep 29

Circulating Tumor DNA in Non–Small-Cell Lung Cancer: A Primer for the Clinician

Oncotarget,

Monitoring of KRAS-mutated ctDNA to discriminate pseudo-progression from true progression during anti-PD-1 treatment of lung adenocarcinoma.

Nature, 2017-04-26

Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.

The New England journal of medicine, 2016-11-10

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

N Engl J Med, 2017 Nov 16

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

The New England journal of medicine, 2017-06-22

First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.

Radiat Oncol, 2015 Apr 26

Radiation-induced bronchiolitis obliterans organizing pneumonia (BOOP) syndrome in breast cancer patients is associated with age.

The New England journal of medicine, 2017-12-28

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

Nature, 2013-07-11

Mutational heterogeneity in cancer and the search for new cancer-associated genes.

The Lancet. Oncology, 2017-07

Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.

International journal of radiation oncology, biology, physics, 2017-06-01

Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy.

JAMA oncology, 2018-01-11

Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.

The New England journal of medicine, 2018-12-13

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.

Future Oncol, 2019 Apr 25

Radiologic features of pneumonitis associated with nivolumab in non-small-cell lung cancer and malignant melanoma.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2015-12-15

Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study.

Radiation oncology (London, England), 2014-09-19

Stereotactic body radiation therapy (SBRT) for lung cancer patients previously treated with conventional radiotherapy: a review.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-06-01

Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.

International journal of radiation oncology, biology, physics, 2018-08-01

Safety of Combined Immunotherapy and Thoracic Radiation Therapy: Analysis of 3 Single-Institutional Phase I/II Trials.

Int. J. Radiat. Oncol. Biol. Phys., 2016 Jul 15

A Prospective Clinical Trial Combining Radiation Therapy With Systemic Immunotherapy in Metastatic Melanoma.

Eur. Respir. J., 2018 Jan 04

Immunotherapy and pulmonary toxicities: can concomitant immune-checkpoint inhibitors with radiotherapy increase the risk of radiation pneumonitis?

Practical radiation oncology, 2018

Thoracic reirradiation with SBRT for residual/recurrent and new primary NSCLC within or immediately adjacent to a prior high-dose radiation field.

JAMA Oncol, 2019 Jul 11

Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial.

J Thorac Oncol, 2020 Sep 08

Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLC.

The Lancet. Oncology, 2016-07

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.

J Thorac Oncol, 2019 Feb 16

Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors.

Int. J. Radiat. Oncol. Biol. Phys., 2019 Aug 31

Frequent use of local therapy underscores need for multidisciplinary care in the management of patients with melanoma brain metastases treated with PD-1 inhibitors.

Lung Cancer, 2019 Jan 15

Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-04-01

Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.

The New England journal of medicine, 2018-08-23

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.

JAMA oncology, 2017-06-01

Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA).

Neuro-oncology, 2019-02-23

The Impact of Sequencing PD-1/PD-L1 Inhibitors and Stereotactic Radiosurgery for Patients with Brain Metastasis.

Semin. Cancer Biol., 2019 Jul 19

Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review.

J Natl Compr Canc Netw,

Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-06-10

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

J Immunother Cancer, 2019 Aug 22

Concurrent therapy with immune checkpoint inhibitors and TNFα blockade in patients with gastrointestinal immune-related adverse events.

Journal for immunotherapy of cancer, 2017-11-21

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.

Cancer management and research, 2017

Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis.

Lancet Oncol., 2020 Mar 03

Risk of COVID-19 for patients with cancer.

Lancet, 2020 Feb 07

Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury.

Ann. Rheum. Dis., 2019 Sep 20

Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation.

J Immunother Cancer, 2021 Feb

Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade.

J Natl Compr Canc Netw,

NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020.

Ann Oncol,

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

J Immunother Cancer,

Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes.

J Immunother Cancer,

Real-world insights on preferred treatments for steroid-refractory immune checkpoint inhibitor-induced pneumonitis.

J Clin Oncol, 2021 Dec 20

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.

J Natl Compr Canc Netw,

Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology.

N. Engl. J. Med., 2017 Jun 04

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.

The New England journal of medicine, 2018-08-23

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.

N. Engl. J. Med.,

Pembrolizumab for Early Triple-Negative Breast Cancer.

N Engl J Med, 2021 Jun 03

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

Lancet Oncol, 2020 Aug 06

Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.

The Lancet. Oncology, 2018-04

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.

JAMA Oncol,

Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial.

JCO Oncol Pract, 2022 Jan 07

Q and A: A New Standard of Care for Germline and/or Mutation Carriers With Early-Stage Breast Cancer.

Cancer, 2022 Apr 05

Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2018-04

Safety of Combined PD-1 Pathway Inhibition and Intracranial Radiation Therapy in Non-Small Cell Lung Cancer.

J Thorac Oncol, 2021 May 05

Immunotherapy as Single Treatment for Patients With NSCLC With Brain Metastases: A Systematic Review and Meta-Analysis-the META-L-BRAIN Study.

Lancet, 2021 Jun 05

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.

J Clin Oncol, 2021 Dec 03

Low Programmed Death-Ligand 1-Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma.

JAMA Oncol,

Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial.

Lancet Oncol, 2022 Jan 11

Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.

Lancet,

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.

Ann Pharmacother, 2021 Jul 20

Impact of Proton Pump Inhibitor Use on the Effectiveness of Immune Checkpoint Inhibitors in Advanced Cancer Patients.

Ann Transl Med,

The effect of proton pump inhibitor uses on outcomes for cancer patients treated with immune checkpoint inhibitors: a meta-analysis.

Can Fam Physician,

Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline.

JAMA Netw Open, 2022 Feb 01

Outcomes Among Patients With or Without Obesity and With Cancer Following Treatment With Immune Checkpoint Blockade.

J Clin Oncol, 2021 May 03

Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update.

The Lancet. Oncology, 2018-03

Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis.

Nature medicine, 2019-01

Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade.

J Immunother Cancer,

Obesity diminishes response to PD-1-based immunotherapies in renal cancer.

Exp Hematol Oncol, 2021 Feb 19

Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy.

Melanoma research, 2017-04

Antiphospholipid syndrome associated with combined immune checkpoint inhibitor therapy.

Lung Cancer, 2021 Aug 03

Antiphospholipid syndrome-induced ischemic stroke following pembrolizumab: Case report and systematic review.

SAGE Open Med Case Rep, 2020 Nov 06

Severe mesenteric ischemia with multiple organ failure in a patient previously treated with a humanized monoclonal antibody against programmed death receptor-1 (pembrolizumab), a case of pembrolizumab associated catastrophic antiphospholipid syndrome?

Lancet Oncol, 2019 Jan

New therapeutic perspectives to manage refractory immune checkpoint-related toxicities.

J Clin Oncol, 2019 Nov 04

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.

J Immunother Cancer, 2022 Jan

Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study.

J Clin Oncol, 2022 Jan 06

Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2015-05

Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis.

J Immunother Cancer, 2021 Jul

Timing of steroid initiation and response rates to immune checkpoint inhibitors in metastatic cancer.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2016 Jul 07

Azathioprine and Risk of Skin Cancer in Organ Transplant Recipients: Systematic Review and Meta-Analysis.

Arthritis & rheumatology (Hoboken, N.J.), 2019 Oct 21

Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study.

European journal of cancer (Oxford, England : 1990), 2023 Dec 28

Effects of an immunosuppressive therapy on the efficacy of immune checkpoint inhibition in metastatic melanoma - An analysis of the prospective skin cancer registry ADOREG.

Arthritis and rheumatism, 2006 Mar

Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis.

Immunotherapy

Questions discussed in this category

Papers discussed in this category

Related Topics